SM04554 (Dalosirvat): Wnt Pathway Activator – Mechanism, Solubility & Research Guide

SM04554 is the development code for Dalosirvat (CAS 1360540-81-3, C₁₈H₁₆O₄, MW 296.32) — a small-molecule direct Wnt/β-catenin pathway activator with EC₅₀ 28–29 nM in cell-based reporter assays. It is not a vasodilator (Minoxidil), not a CRTH2 antagonist (Setipiprant), not an androgen-receptor antagonist (RU58841) — it works on a different biological pathway with a different molecular weight, a different solubility profile, and a different clinical trajectory. This guide covers the chemistry, the stock-solution failure modes, and the head-to-head comparison a procurement manager needs before sourcing research material.

1. What Is SM04554 (Dalosirvat)?

SM04554 is the Biosplice (formerly Samumed) development code for Dalosirvat, a synthetic small molecule disclosed as compound 1 in patent WO2012024404A1 and progressed into three clinical trials for androgenetic alopecia before the company cancelled the programme after the Phase 3 read-out in 2023. The molecule is structurally a 1,4-diketone bridging a 2,3-dihydro-1,4-benzodioxin-6-yl group on one side and a phenyl group on the other; the IUPAC name is 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-phenylbutane-1,4-dione.

The compound is supplied as the free molecule — no salt form is in commercial circulation — and is sold under research-use-only terms at research (5 mg – 100 mg), custom (up to 1 G) and bulk (1 G / 10 G / 100 G / 1 KG / 10 KG) pack sizes. The mechanism of action is direct activation of the canonical Wnt/β-catenin signalling pathway; the EC₅₀ in cell-based TOP-Flash reporter assays is 28–29 nM.

1.1 Chemical Profile & Basic Specs

1.2 Origin & Clinical Background

SM04554 was disclosed by Samumed (rebranded Biosplice Therapeutics in 2020) and entered the clinic as a topical 0.15 % / 0.25 % solution for androgenetic alopecia. The reported Phase 2 data showed that only the 0.15 % concentration produced a statistically meaningful change versus vehicle; the 0.25 % arm did not. A 625-patient Phase 3 trial (NCT03742518) was reportedly initiated in 2018; the compound completed a Phase 3 read-out in early 2023 and Biosplice cancelled the dalosirvat programme based on those results. The most recent public update (October 2025) records no further disclosed trials.

2. SM04554 Physicochemical Properties

The single largest practical driver of any SM04554 stock-solution protocol is solubility. The compound is freely soluble in anhydrous DMSO at 83.33 mg/mL (281.22 mM) with ultrasonication, sparingly soluble in ethanol and methanol, and practically insoluble in water and aqueous buffers. Repeated opening of the bulk container under ambient humidity picks up surface moisture and accelerates degradation, because the compound is hygroscopic.

2.1 Solubility & Stock Solution Preparation

The standard 10 mM stock for cell-based reporter assays is prepared in anhydrous DMSO at 2.96 mg/mL. The DMSO stock is stable 24 months at −80 °C and 12 months at −20 °C, protected from light and from repeated freeze-thaw cycles. Working solutions in cell-culture media are prepared by dilution of the DMSO stock into pre-warmed media at a final DMSO concentration ≤ 0.1 % v/v; higher DMSO concentrations can interfere with the Wnt reporter readout in some cell systems.

For in vivo dosing, the published vehicle is 10 % DMSO + 40 % PEG300 + 5 % Tween-80 + 45 % saline, which yields a clear solution at ≥ 2.08 mg/mL (7.02 mM). The compound is also compatible with 20 % SBE-β-CD in saline and with corn oil at ≥ 2.5 mg/mL.

3. SM04554 vs Other Hair Research Compounds

The four compounds most frequently named in hair research procurement — SM04554, Minoxidil, Setipiprant and RU58841 — work on four different biological pathways. They are not interchangeable in a hair research workflow, and a quotation issued against one cannot be substituted for another.

3.1 SM04554 vs Minoxidil

The two compounds address different nodes of the hair-growth pathway and produce different biological readouts at different concentrations on different cell systems.

Mechanism difference: SM04554 activates the Wnt/β-catenin pathway directly, driving β-catenin nuclear translocation and TCF/LEF reporter activity. Minoxidil opens K_ATP channels, producing membrane hyperpolarisation in vascular smooth muscle and dermal papilla cells, and requires metabolic activation by follicular sulfotransferase to its active sulphate form — the rate-limiting step for any non-responder. The two compounds have no shared mechanism and produce non-overlapping biological signatures.

Solubility & formulation difference: SM04554 is freely soluble in DMSO (83.33 mg/mL) but practically insoluble in water. Minoxidil is moderately soluble in DMSO (2–3.6 mg/mL) and ethanol (~7 mg/mL), and insoluble in water. Both require co-solvent vehicles for cell-based work; the standard SM04554 vehicle is 10 % DMSO + 40 % PEG300 + 5 % Tween-80 + 45 % saline; the standard Minoxidil vehicle is propylene glycol / ethanol / water at the cosmetic-grade ratio.

Research application scenarios: SM04554 fits Wnt-pathway reporter screens (TOP-Flash), anagen-induction in human hair follicle organ culture, β-catenin nuclear translocation assays, and Axin2/Lef1 qPCR. Minoxidil fits dermal papilla cell proliferation, K_ATP channel opening assays, sulfotransferase activity assays, and cutaneous blood-flow imaging.

3.2 SM04554 vs Setipiprant

SM04554 and Setipiprant address different mechanisms (Wnt activation vs prostaglandin-D2 receptor antagonism), have different molecular weights (296.32 vs 402.42 g/mol), different solubilities, and different clinical trajectories.

Target pathway: SM04554 acts upstream of follicle stem-cell activation by direct Wnt/β-catenin agonism. Setipiprant acts on the prostaglandin-D2 signalling axis by blocking the DP2/CRTH2 receptor that drives Th2-cell activation, eosinophil chemotaxis, and (in hair follicle biology) follicle miniaturisation. The two compounds sit on different branches of the same overall hair-growth pathway and produce distinct biological signatures.

Molecular properties & handling: SM04554 is hygroscopic and light-sensitive; storage at −20 °C in amber containers is the standard. Setipiprant is more chemically stable at ambient temperature in powder form but requires the same DMSO dilution protocol for cell-based work; the standard 10 mM Setipiprant stock is 4.02 mg/mL in DMSO. The Setipiprant Phase 2A AGA study completed in May 2018 in males 18–49 did not find statistically significant improvement versus placebo; the asthma and allergic rhinitis programmes were discontinued earlier. Setipiprant remains research-only.

3.3 SM04554 vs RU58841

RU58841 (PSK-3841) is a non-steroidal androgen-receptor antagonist designed for topical application. It is the most mechanistically distinct of the four compounds and is not a hair-growth stimulant in the same sense as the other three.

Mechanism: SM04554 activates the Wnt pathway; RU58841 binds the androgen receptor (K_d 1.1–1.8 nM at the hamster flank-organ AR) and prevents DHT-driven follicle miniaturisation. The two compounds are functionally opposite in one sense — SM04554 activates follicle stem-cell cycling; RU58841 blocks the androgen signal that drives miniaturisation. In a research workflow, RU58841 sits closer to a finasteride-class mechanism (anti-androgen) than to a Wnt activator.

4. Critical Handling & Storage Guidelines

SM04554 is hygroscopic, light-sensitive, and subject to surface oxidation. The handling profile differs from Minoxidil (more stable, less hygroscopic) and from Setipiprant (more chemically robust but still light-sensitive at scale). Three specific failure modes recur in the literature.

4.1 Light sensitivity risk

UV and ambient light degrade SM04554 in solution and at the solid surface. Standard storage is in amber borosilicate vials or amber screw-cap polypropylene tubes; clear glass vials are not appropriate. Light-protected DMSO stocks in amber vials are stable 24 months at −80 °C and 12 months at −20 °C. Working solutions in clear plates exposed to ambient laboratory light for > 4 h show measurable drift in the TOP-Flash readout.

4.2 Moisture requirement

SM04554 is hygroscopic. Bulk containers should be opened only in a glove box or under dry air; opened containers left at ambient humidity pick up surface moisture within minutes, accelerating degradation. The procurement specification should include a desiccant sachet in every shipment at every pack size; the inner container should be heat-sealed in aluminium foil pouches. Storage is −20 °C, desiccated, protected from light.

4.3 Freeze-thaw warning

Repeated freeze-thaw cycles of DMSO stocks reduce shelf life. Each freeze-thaw introduces water from condensation on the vial thread and accelerates degradation of the parent compound. Standard practice is to aliquot the 10 mM DMSO stock into single-use amber screw-cap vials at 50–100 µL per vial, so that each assay uses a freshly thawed vial that is not refrozen.

5. Supplier Red Flags When Buying SM04554

Five patterns recur in the SM04554 procurement record. None is unique to this compound, but the photolability and hygroscopicity make SM04554 particularly susceptible to supplier-side compromise.

1. Fake high-purity claims. A CoA that quotes HPLC purity alone, without NMR and LC-MS confirmation, is not sufficient for a Wnt-pathway mechanism screen. The most common pattern is a 99 % HPLC area report on a chromatogram that does not show the parent peak cleanly resolved from the solvent front. The procurement hygiene step is to demand 1H NMR, LC-MS accurate mass of the parent ion (theoretical m/z 297.1121 for [M+H]+), and HPLC with a published method.
2. Cosmetic-grade powder. SM04554 is supplied under research-use-only terms from RUO producers; the same supply chain that fills cosmetic-grade raw-material drums is not a research supplier. A quotation that lists "SM04554 1 kg, cosmetic grade, for topical serum formulation" is not a research-grade quote and should be rejected at intake. The end-use statement must explicitly read "research use only — not for human or veterinary use."
3. Clear glass vials. Photodegradation in clear glass during ocean freight has produced batches that fall below the acceptance HPLC purity at intake despite a passing CoA at the supplier site. The procurement specification must fix amber borosilicate vials or amber polypropylene tubes at every pack size.
4. Misleading marketing. Marketing copy that frames SM04554 as a "hair growth serum" or "topical treatment" implies a finished consumer product — which it is not. Research-grade supply should carry an RUO end-use statement and a research-only safety data sheet; a finished-product SDS indicates cosmetic-grade material. The two supply chains should not be confused.
5. Missing batch stability data. A CoA that shows identity and purity but does not include accelerated stability (40 °C / 75 % RH, 4 weeks) or a real-time stability trend at −20 °C over 12 months leaves shelf life as an unverified claim. Photolabile and hygroscopic compounds require supplier-side stability data to support the catalogue shelf-life statement.

6. Frequently Asked Questions

7. Final Verdict: SM04554 vs Minoxidil vs Setipiprant vs RU58841

For a Wnt-pathway reporter screen, an anagen-induction assay in human hair follicle organ culture, or any β-catenin / Axin2 / Lef1 readout — SM04554 is the right default. EC₅₀ 28–29 nM in the TOP-Flash assay, free solubility in DMSO at 83 mg/mL, and the only direct Wnt activator in the four-compound comparison. The hygroscopicity and light-sensitivity demand amber containers, desiccation and single-use DMSO aliquots, but the procurement specification is straightforward at the standard 1 G / 10 G / 100 G / 1 KG / 10 KG pack sizes.

For dermal papilla viability assays, K_ATP channel opening studies, or any cutaneous blood-flow work — Minoxidil is the right reference standard. The compound is FDA-approved, USP / EP monographed, and freely available at research-grade purity with a clean pharmacology record. The K_ATP channel mechanism is distinct from the Wnt activator mechanism, and Minoxidil's vasodilator profile is the dominant side effect that any cell-based work must control for.

For CRTH2/DP2 receptor binding assays, Th2-cytokine release studies, or prostaglandin-D2 signalling work — Setipiprant is the right probe. IC₅₀ 6 nM at the human DP2 receptor, oral human half-life of ~11 h, and a clean selectivity profile over DP1 / EP2 / EP4. The 2018 Phase 2A AGA read-out was negative and the programme is dormant, but the compound remains a gold-standard research probe for the CRTH2 pathway.

For androgen-receptor binding in skin, flank-organ androgen-response studies, or any topical antiandrogen mechanism — RU58841 is the right reference standard. K_d 1.1–1.8 nM at the androgen receptor, rapid systemic clearance (~1 h), and topical-only profile that avoids the systemic anti-androgen confounders seen with bicalutamide or finasteride. The compound was never approved and is supplied under RUO only.

The four are not interchangeable in any hair research workflow, and a quotation issued against one cannot be substituted for another. The decision is mechanism-dependent and assay-dependent; the procurement specification depends on CAS, molecular target, and pack size being consistent across the catalogue.